与晚期,上皮卵巢,原发性腹膜或输卵管癌中的NAB-磷脂和贝伐单抗结合使用的透明剂
在晚期,上皮卵巢,原发性腹膜或输卵管癌(Bella)中与NAB-甲氟甲酰胺和贝伐单抗结合的2阶段研究
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
研究概览
地位
详细说明
This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.
For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Corcept Therapeutics
- 电话号码:650-414-2314
- 邮箱:corceptstudy557@corcept.com
学习地点
-
-
-
Aachen、德国、52074
- 招聘中
- 519
-
Berlin、德国、10117
- 招聘中
- 255
-
Kempten、德国、87439
- 招聘中
- 520
-
-
-
-
-
Catania、意大利、95126
- 招聘中
- 321
-
Milan、意大利、20141
- 招聘中
- 122
-
Milan、意大利、20159
- 招聘中
- 516
-
Pavia、意大利、27100
- 招聘中
- 295
-
Rome、意大利、00168
- 招聘中
- 124
-
Torino、意大利、10128
- 招聘中
- 293
-
Treviso、意大利、31100
- 招聘中
- 319
-
-
-
-
-
Brussels、比利时、1200
- 招聘中
- 109
-
Charleroi、比利时、6000
- 招聘中
- 326
-
Hasselt、比利时、3500
- 招聘中
- 325
-
Leuven、比利时、3000
- 招聘中
- 108
-
-
Belgium
-
Aalst、Belgium、比利时、9300
- 招聘中
- 328
-
-
-
-
-
Lille、法国、59000
- 招聘中
- 306
-
Nancy、法国、54100
- 招聘中
- 307
-
Nice、法国、06100
- 招聘中
- 310
-
Pierre-Bénite、法国、69495
- 招聘中
- 324
-
Plérin、法国、22190
- 招聘中
- 323
-
Toulouse、法国、31059
- 招聘中
- 308
-
-
-
-
-
Gdynia、波兰、81-519
- 招聘中
- 341
-
Siedlce、波兰、08-MO
- 招聘中
- 329
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- 招聘中
- 004
-
-
California
-
Palo Alto、California、美国、94304
- 招聘中
- 150
-
San Francisco、California、美国、94109
- 招聘中
- 278
-
San Francisco、California、美国、94143
- 招聘中
- 014
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- 032
-
-
Florida
-
Fort Myers、Florida、美国、33901
- 招聘中
- 544
-
Miami Beach、Florida、美国、33140
- 招聘中
- 335
-
West Palm Beach、Florida、美国、33041
- 招聘中
- 543
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- 001
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55404
- 招聘中
- 518
-
-
Missouri
-
Kansas City、Missouri、美国、64132
- 招聘中
- 334
-
St Louis、Missouri、美国、63110
- 招聘中
- 521
-
-
New Mexico
-
Albuquerque、New Mexico、美国、97102
- 招聘中
- 292
-
-
Ohio
-
Centerville、Ohio、美国、45459
- 招聘中
- 304
-
-
Oregon
-
Eugene、Oregon、美国、97401
- 招聘中
- 517
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15213
- 招聘中
- 127
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- 522
-
Norfolk、Virginia、美国、23502
- 招聘中
- 300
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- 121
-
-
-
-
-
Badalona、西班牙、08916
- 招聘中
- 349
-
Barcelona、西班牙、08035
- 招聘中
- 115
-
Madrid、西班牙、28034
- 招聘中
- 114
-
Valencia、西班牙、46026
- 招聘中
- 330
-
Valencia、西班牙、46010
- 招聘中
- 558
-
-
-
-
Gangnam-gu
-
Seoul、Gangnam-gu、韩国、06351
- 招聘中
- 396
-
-
Goyang-si
-
Gyeonggi-do、Goyang-si、韩国、10408
- 招聘中
- 397
-
-
Jongno-gu
-
Seoul、Jongno-gu、韩国、03080
- 招聘中
- 399
-
-
Seocho-gu
-
Seoul、Seocho-gu、韩国、06591
- 招聘中
- 523
-
-
Seodaemun-gu
-
Seoul、Seodaemun-gu、韩国、03722
- 招聘中
- 398
-
-
Songpa-gu
-
Seoul、Songpa-gu、韩国、05505
- 招聘中
- 403
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Arms A and B
- Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Arm A Only: Platinum-resistant disease
- Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
- Life expectancy of ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Arm C
- Stage III or IV, recurrent, or metastatic endometrial cancer
- Life expectancy of ≥3 months
- ECOG performance status of 0 or 1
- Able to swallow and retain oral medication
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
- Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Exclusion Criteria:
Arm A and B
- Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
Arm C
- Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
- Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab
In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
其他名称:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
实验性的:Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab
In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
其他名称:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
实验性的:Arm C: Relacorilant in Combination with Nab-Paclitaxel
In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
其他名称:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival (PFS)
大体时间:Date of first dose until PD or death, up to 18 months
|
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first. |
Date of first dose until PD or death, up to 18 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
一个或多个不良事件的患者数量
大体时间:上次剂量后30天的初次剂量的日期
|
上次剂量后30天的初次剂量的日期
|
|
|
Objective Response Rate (ORR)
大体时间:Date of first dose until PD or death, up to 18 months
|
To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
Date of first dose until PD or death, up to 18 months
|
|
Best Overall Response Rate (BOR)
大体时间:Date of first dose until PD or death, up to 18 months
|
To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death. |
Date of first dose until PD or death, up to 18 months
|
|
Duration of Response (DOR)
大体时间:Time of first objective response until PD or death, up to 18 months
|
To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first. |
Time of first objective response until PD or death, up to 18 months
|
|
Clinical Benefit Rate (CBR)
大体时间:Week 24
|
To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1. |
Week 24
|
|
Overall Survival (OS)
大体时间:Date of first dose up to 6, 12, and 18 months
|
To evaluate the probability of OS survival at 6, 12, and 18 months. |
Date of first dose up to 6, 12, and 18 months
|
|
Area under the plasma concentration-time curve (AUC) of relacorilant
大体时间:On Cycle 1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 1 Day 8 (each cycle is 28 days)
|
|
Maximum plasma concentration (Cmax) of relacorilant
大体时间:On Cycle1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle1 Day 8 (each cycle is 28 days)
|
|
Trough plasma concentrations (Cmin) of relacorilant
大体时间:On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
合作者和调查者
调查人员
- 研究主任:Danny Nguyen, MD、Corcept Therapeutics
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- CORT125134-557
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.